Solace Therapeutics, Inc. Adds New Member to Board of Directors

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Solace Therapeutics, a venture capital funded medical technology company focusing on treating stress urinary incontinence (SUI), announced today that Stacy Enxing Seng has joined the Board of Directors. She serves on the board alongside Ryan Drant, General Partner with New Enterprise Associates (NEA); Ali Behbahani MD, Principal at NEA; John McDonough, CEO at T2 Biosystems; and Kevin G. Connors, founding partner of Spray Venture Partners.

Enxing Seng is President of Covidien's Vascular Therapies Global Business Unit, an organization of 4,000 employees with $1.4 billion in revenue. She joined Covidien in July 2010 through Covidien's acquisition of ev3, where she was a founding member and executive officer and led ev3's Peripheral Vascular Division from inception to a $350 million business. Prior to joining ev3, Stacy held various positions at Boston Scientific, SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. She received an MBA from Harvard University and a bachelor's degree from Michigan State University.

"We are excited about Stacy joining our Board of Directors. Stacy has a proven track record in leading and growing businesses," said Bill Gruber, President and CEO at Solace Therapeutics. "As the Company continues to execute plans for commercialization of the Solace Bladder Control SystemTM, Stacy's experience and leadership will be instrumental in the Company's success."


Solace Therapeutics is an emerging women's health company that is focused on a revolutionary non-surgical office-based treatment for symptoms of female SUI. SUI, the most prevalent form of incontinence among women, affects an estimated 15 million adult women in the U.S. Most women believe that it is a normal part of aging. These women choose to manage their SUI by utilizing absorbent products such as protective pads versus seeking medical help. Solace is dedicated to improving the quality of life for women whose daily life is disrupted by their incontinence. Please visit to learn more about Solace.


Solace Therapeutics
Nicole M. Shugrue, 508-283-1200 Ext. 165
Vice President, Marketing
[email protected]


Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.